Brief: Caribou Biosciences Announces FDA Clearance Of Ind Application For Cb-011, An Allogeneic Anti-Bcma Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma
21/11/2022 14:42
Nov 21 (Reuters) - Caribou Biosciences Inc CRBU.O :
* CARIBOU BIOSCIENCES ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY FOR THE
TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA
* CARIBOU BIOSCIENCES INC - CAMMOUFLAGE PHASE 1 CLINICAL
TRIAL TO
INITIATE PATIENT ENROLLMENT AT DOSE LEVEL 1 IN EARLY 2023
Source text for Eikon: ID:nGNX3TLVBR
Further company coverage: CRBU.O
((Reuters.Briefs@thomsonreuters.com;))